清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial

医学 内科学 转移性尿路上皮癌 肿瘤科 临床终点 实体瘤疗效评价标准 尿路上皮癌 临床研究阶段 顺铂 化疗 临床试验 癌症 膀胱癌
作者
Evan Y. Yu,Daniel P. Petrylak,Peter H. O’Donnell,Jae‐Lyun Lee,Michiel S. van der Heijden,Yohann Loriot,Mark N. Stein,Andrea Necchi,Takahiro Kojima,Michael R. Harrison,Se Hoon Park,David I. Quinn,Elisabeth I. Heath,Jonathan E. Rosenberg,Joyce Steinberg,Shang-Ying Liang,Janet Trowbridge,Mary S. Campbell,Bradley A. McGregor,Arjun Vasant Balar
出处
期刊:Lancet Oncology [Elsevier]
卷期号:22 (6): 872-882 被引量:164
标识
DOI:10.1016/s1470-2045(21)00094-2
摘要

Summary

Background

Locally advanced or metastatic urothelial carcinoma is generally incurable and has scarce treatment options, especially for cisplatin-ineligible patients previously treated with PD-1 or PD-L1 therapy. Enfortumab vedotin is an antibody–drug conjugate directed at Nectin-4, a protein highly expressed in urothelial carcinoma. We aimed to evaluate the efficacy and safety of enfortumab vedotin in the post-immunotherapy setting in cisplatin-ineligible patients.

Methods

EV-201 is a multicentre, single-arm, phase 2 study of enfortumab vedotin in patients with locally advanced or metastatic urothelial carcinoma previously treated with PD-1 or PD-L1 inhibitors. Cohort 2 included adults (aged ≥18 years) with an Eastern Cooperative Oncology Group performance status score of 2 or less who were considered ineligible for cisplatin at enrolment and who had not received platinum-containing chemotherapy in the locally advanced or metastatic setting. Enfortumab vedotin was given intravenously at a dose of 1·25 mg/kg on days 1, 8, and 15 of every 28-day cycle. The primary endpoint was confirmed objective response rate per Response Evaluation Criteria in Solid Tumours version 1.1 assessed by blinded independent central review. Efficacy and safety were analysed in all patients who received at least one dose of enfortumab vedotin. EV-201 is an ongoing study and the primary analysis is complete. This study is registered with Clinicaltrials.gov, NCT03219333.

Findings

Between Oct 8, 2017, and Feb 11, 2020, 91 patients were enrolled at 40 sites globally, of whom 89 received treatment. Median follow-up was 13·4 months (IQR 11·3–18·9). At data cutoff (Sept 8, 2020), the confirmed objective response rate was 52% (46 of 89 patients; 95% CI 41–62), with 18 (20%) of 89 patients achieving a complete response and 28 (31%) achieving a partial response. 49 (55%) of 89 patients had grade 3 or worse treatment-related adverse events. The most common grade 3 or 4 treatment-related adverse events were neutropenia (eight [9%] patients), maculopapular rash (seven [8%] patients), and fatigue (six [7%] patients). Treatment-related serious adverse events occurred in 15 (17%) patients. Three (3%) patients died due to acute kidney injury, metabolic acidosis, and multiple organ dysfunction syndrome (one [1%] each) within 30 days of first dose and these deaths were considered by the investigator to be related to treatment; a fourth death from pneumonitis occurred more than 30 days after the last dose and was also considered to be related to treatment.

Interpretation

Treatment with enfortumab vedotin was tolerable and confirmed responses were seen in 52% of cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma who were previously treated with PD-1 or PD-L1 inhibitors. These patients have few treatment options, and enfortumab vedotin could be a promising new therapy for a patient population with a high unmet need.

Funding

Astellas Pharma Global Development and Seagen.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
17852573662完成签到,获得积分10
10秒前
22秒前
25秒前
诚心的水杯完成签到 ,获得积分10
28秒前
31秒前
光亮的自行车完成签到 ,获得积分10
35秒前
春华秋实完成签到,获得积分10
36秒前
renxuda发布了新的文献求助10
46秒前
sunny完成签到 ,获得积分10
50秒前
无辜的行云完成签到 ,获得积分0
1分钟前
jerry完成签到 ,获得积分10
1分钟前
wanci应助佳哥闯天下采纳,获得10
1分钟前
1分钟前
DayFu完成签到 ,获得积分10
1分钟前
稳重元菱发布了新的文献求助10
1分钟前
2分钟前
爱的魔力转圈圈完成签到,获得积分10
2分钟前
2分钟前
佳哥闯天下完成签到,获得积分20
2分钟前
打打应助稳重元菱采纳,获得10
2分钟前
子蓼完成签到 ,获得积分10
2分钟前
微卫星不稳定完成签到 ,获得积分0
2分钟前
3分钟前
puzhongjiMiQ发布了新的文献求助10
3分钟前
zzhui完成签到,获得积分10
3分钟前
毛毛弟完成签到 ,获得积分10
3分钟前
潘fujun完成签到 ,获得积分10
4分钟前
颜路完成签到,获得积分10
4分钟前
可夫司机完成签到 ,获得积分10
4分钟前
chichenglin完成签到 ,获得积分10
4分钟前
大水完成签到 ,获得积分10
4分钟前
润润润完成签到 ,获得积分10
4分钟前
希勤发布了新的文献求助10
5分钟前
zijingsy完成签到 ,获得积分10
5分钟前
Sunnpy完成签到 ,获得积分10
5分钟前
希勤发布了新的文献求助10
5分钟前
5分钟前
稳重元菱发布了新的文献求助10
5分钟前
DJ_Tokyo完成签到,获得积分10
5分钟前
Eid完成签到,获得积分10
6分钟前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Le dégorgement réflexe des Acridiens 800
Defense against predation 800
XAFS for Everyone (2nd Edition) 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3134020
求助须知:如何正确求助?哪些是违规求助? 2784845
关于积分的说明 7768807
捐赠科研通 2440219
什么是DOI,文献DOI怎么找? 1297340
科研通“疑难数据库(出版商)”最低求助积分说明 624925
版权声明 600792